Predicting arrhythmic event score in Brugada syndrome: Worldwide pooled analysis with internal and external validation

Brugada syndrome is an inherited arrhythmic disease associated with major arrhythmic events (MAE). Risk predictive scores were previously developed with various performances. The purpose of this study was to create a novel score—Predicting Arrhythmic evenT (PAT)—with internal and external validation...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Heart rhythm 2023-10, Vol.20 (10), p.1358-1367
Hauptverfasser: Rattanawong, Pattara, Mattanapojanat, Natthinee, Mead-Harvey, Carolyn, Van Der Walt, Charles, Kewcharoen, Jakrin, Kanitsoraphan, Chanavuth, Vutthikraivit, Wasawat, Prasitlumkum, Narut, Putthapiban, Prapaipan, Chintanavilas, Kumpol, Sahasthas, Dujdao, Ngarmukos, Tachapong, Thakkinstian, Ammarin, Sorajja, Dan, Makarawate, Pattarapong, Shen, Win-Kuang
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Brugada syndrome is an inherited arrhythmic disease associated with major arrhythmic events (MAE). Risk predictive scores were previously developed with various performances. The purpose of this study was to create a novel score—Predicting Arrhythmic evenT (PAT)—with internal and external validation. A systematic review was performed to identify risk factors for MAE. The odds ratios (ORs) of each factor were pooled across studies. The PAT scoring scheme was developed based on pooled ORs. The PAT score was internally validated with published 105 Asian patients (follow-up 8.0 ± 4.1 [SD] years) and externally validated with unpublished 164 multiracial patients (82.3% White, 14.6% Asian, 3.2% Black; mean follow-up 8.0 ± 6.9 years) with Brugada syndrome. Performances were assessed and compared with previous scores using receiver operating characteristic curve (ROC) analysis. Sixty-seven studies published between 2002 and 2022 from 26 countries (7358 patients) were included. Pooled ORs were estimated, indicating that 15 of 23 risk factors were significant. The PAT score was then developed accordingly. The PAT score had significantly better discrimination (ROC 0.9671) than the BRUGADA-RISK score (ROC 0.7210; P = .006), Shanghai Score System (ROC 0.7079; P = .003), and Sieira et al score (ROC 0.8174; P = .026) in an external validation cohort. PAT score ≥ 10 predicted the first MAE with 95.5% sensitivity and 89.1% specificity (ROC 0.9460) and the recurrent MAE (ROC 0.7061) with 15.4% sensitivity and 93.3% specificity. The PAT score was shown to be useful in predicting MAE for primary prevention in patients with Brugada syndrome. [Display omitted]
ISSN:1547-5271
1556-3871
1556-3871
DOI:10.1016/j.hrthm.2023.06.013